ALA

Arovella Therapeutics

Pharmaceuticals, Biotechnology & Life Sciences

Arovella Therapeutics Limited is a biotechnology company developing a platform of invariant Natural Killer T (iNKT) cells for treating cancer. The company aims to harness this platform to create innovative and targeted cancer therapies, positioning itself at the forefront of biotechnology advances. Arovella's unique approach targets unmet medical needs, offering potential breakthroughs in cancer t...

biotechnology

cancer treatment

cell therapy

pharmaceuticals

Shorted

short percentage0.05%

reported shorts544.6K

shares on issue1.201B

About

website

arovella.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Suite 1, Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053

Connect

Key Metrics

market cap

$120.12M

price$0.10

eps$-0.01

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

biotechnology

cancer treatment

cell therapy

pharmaceuticals

innovative medicine

Company Overview

AI-generated company summary

Company History

Founded in 1995, Arovella Therapeutics initially entered the market with a focus on oral-release drug delivery systems. Over time, the company pivoted towards biotechnology and adopted a strong focus on oncology, leading to the development of its proprietary iNKT cell platform. Arovella was listed on the Australian Stock Exchange (ASX) under the ticker code ALA. The company has since made significant strides in advancing its iNKT cell therapies through various stages of clinical development.

Competitive Advantages

Arovella boasts proprietary iNKT cell platform technology, enabling targeted cancer treatments with potentially greater efficacy. The company has strong partnerships with leading research institutions, reinforcing its research and development capabilities. Additionally, Arovella's focus on niche cancer therapies positions it strategically within the evolving biotechnology landscape.

Risk Factors

•High dependence on successful outcomes in clinical trials
•Significant competition from other biotechnological innovations
•Regulatory challenges in bringing new therapies to market

Recent Developments

Last 6 months

In the past six months, Arovella Therapeutics has advanced its iNKT cell therapy through preclinical stages and announced promising laboratory results. The company has expanded its research activities and formed new collaborations to accelerate the commercialization of its cancer treatment platform.

Key People

Leadership team at Arovella Therapeutics

Dr. Michael Baker

CEO

Dr. Michael Baker, an expert in cellular therapies, leads Arovella Therapeutics with extensive experience in biotechnology and business development. He has played a pivotal role in steering the company's strategic focus towards innovative cancer treatments.

Mr. Simon Leers

CFO

Mr. Simon Leers, the CFO of Arovella Therapeutics, brings a wealth of financial management expertise to the company, bolstered by his background in multinational corporations within the life sciences sector.